Matrix protein of vesicular stomatitis virus: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation

Cancer Gene Therapy

Volumn 20, Issue 3, 2013, Pages 178-185

  Zhou, Y ^a   Wen, F ^a   Zhang, P ^a   Tang, R ^a   Li, Q ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

apoptosis; ascites; gene therapy; matrix protein; vascular endothelial growth factor; vesicular stomatitis virus

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOSOME; MATRIX PROTEIN; MESSENGER RNA; PLASMID VECTOR; SODIUM CHLORIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; BAGG ALBINO MOUSE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; MALIGNANT ASCITES; MOUSE; NONHUMAN; OSMOLARITY; PERITONEUM TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULARIZATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY;

ANIMALS; APOPTOSIS; ASCITES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; MICE; OSMOLAR CONCENTRATION; PERITONEAL NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL MATRIX PROTEINS;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 84875219576     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.7     Document Type: Article

References (48)

1. Taber CW. Tabers Cyclopedic Medical Dictionary. FA Davies Co: Philadelphia (PA), USA, 1965 A-92.
2. Spratt JS, Edwards M, Kubota T, Lindberg R, Tseng MT. Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management. Curr Probl Cancer 1996; 10: 558-584.
3. Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol 2008; 9: 215-233.
4. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840-2848.
5. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2000; 76: 895-904.
6. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001; 75: 3474-3479.
7. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
8. Letchworth GJ, Rodriguez LL, Del cbarrera J. Vesicular stomatitis. Vet J 1999; 157: 239-260.
9. Forger 3rd JM, Bronson RT, Huang AS, Reiss CS. Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system. J Virol 1991; 65: 4950-4958.
10. Huneycutt BS, Bi Z, Aoki CJ, Reiss CS. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 1993; 67: 6698-6706.
11. Sur JH, Allende R, Doster AR. Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis. Vet Pathol 2003; 40: 512-520.
12. Koyama AH. Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res 1995; 37: 285-290.
13. Ahmed M, Lyles DS. Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III. J Virol 1998; 72: 8413-8419.
14. Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 2003; 77: 5524-5528.
15. Lyles DS, McKenzie MO. Activity of vesicular stomatitis virus M protein mutants in cell rounding is correlated with the ability to inhibit host gene expression and is not correlated with virus assembly function. Virology 1997; 229: 77-89.
16. Blondel D, Harmison GG, Schubert M. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J Virol 1990; 64: 1716-1725.
17. Gromeier M, Wimmer E. Viruses for the treatment of malignant glioma. Curr Opin Mol Ther 2001; 3: 503-508.
18. Lin X, Chen X, Wei Y, Zhao J, Fan L, Wen Y et al. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007; 104: 540-546.
19. Luo S et al. Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melonoma. Cancer Sci 2010; 101: 1219-1225.
20. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Parikh AA, Fan F et al. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 2002; 87: 1182-1187.
21. Kobayashi H, Yagyu T, Inagaki K, Kondo T, Suzuki M, Kanayama N et al. Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer. Int J Cancer 2004; 110: 4-139.
22. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993; 53: 3186-3192.
23. Barry MA, Reynolds JE, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 1993; 53: 2349-2357.
24. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G et al. Matrixmetalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224-5229.
25. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
26. Hirabayashi K, Graham J. Genesis of ascites in ovarian cancer. Am J Obstet Gynecol 1970; 106: 492-497.
27. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
28. Garrison RN, Kaelin LD, Heuser LS, Galloway RH. Malignant ascites clinical and experimental observations. Ann Surg 1986; 203: 644-649.
29. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res 1987; 42: 126-132.
30. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor inmouse ascites tumors. Cancer Res 1998; 58: 2652-2660.
31. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998; 58: 2594-2600.
32. Shibuya M, Luo JC, Toyoda M, Yamaguchi S. Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 1999; 43: S72-S77.
33. Liu CD, Tilch L, Kwan D, McFadden DW. Vascular endothelial growth factor is increased in ascites frommetastatic pancreatic cancer. J Surg Res 2002; 102: 31-34.
34. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447-454.
35. Akutagawa N, Nishikawa A, Iwasaki M, Fujimoto T, Teramoto M, Kitajima Y et al. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: Association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res 2002; 93: 644-651.
36. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB et al. Vascular endothelial growth factor immunoneutralization plus paclitaxelmarkedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161: 1917-1924.
37. Yeo KT, Wang HH, Nagy JA, Sioussat SR, Ledbetter SR, Hoogewerf AJ et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993; 53: 2912-2916.
38. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364-3368.
39. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178-187.
40. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumorderived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59: 1592-1598.
41. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995; 55: 360-368.
42. Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002; 62: 2019-2023.
43. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
44. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-5632.
45. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009; 14: 1242-1251.
46. Zhong Q, Wen YJ, Yang HS, Luo H, Fu AF, Yang F et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 2008; 19: 1584-1591.
47. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
48. Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990; 87: 2628-2632.